

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final draft guidance

(when no draft guidance was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equalities issues were identified during the scoping process.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

A stakeholder commented that liver cancer disproportionately affects people from deprived areas and that, if recommended, durvalumab plus gemcitabine and cisplatin should be accessible to all people irrespective of where they live. The committee considered that access to treatments is an implementation issue that cannot be addressed by a technology appraisal recommendation.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No other potential equality issues have been identified by the committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, see section 3.13 of the final draft guidance.

**Approved by Associate Director (name):** Ross Dent

**Date:** 20/10/2023